Faget Comments on FDA Proposal to Streamline Premarket Review Submissions

19 November 2018 MobiHealthNews News
Special Counsel Kyle Faget was quoted in a MobiHealthNews article, "Proposed framework lessens FDA's regulatory requirements for prescription drugs companion apps," about an FDA proposal that would classify most software released by pharmaceutical companies as "promotional labeling" not requiring premarket review.

Faget welcomed the proposed framework, but warned that any confusion regarding appropriate software classification could hamper the end goal of increased digital adoption.

"Sponsors wishing to enter this space will face several decision-points, including determining if the software application is a device subject to regulatory approval and whether the output of such software is FDA-required labeling or promotional labeling," she said. "Confusion on any or all of these points may mean sponsors must avail themselves of FDA's advisory comment process, which very well could have the contradictory effect of deterring software application innovation and use."


Related Services


Will Other Tech Companies Join Microsoft in Honoring CCPA Across the U.S.?
18 November 2019
Internet, IT & e-Discovery Blog
Get Off My Lawn! Employers Gain Expanded Rights to Keep Unions Away from Their Property
18 November 2019
Labor & Employment Law Perspectives
Debunking Conventional Labor and Employment Wisdom
18 November 2019
Labor & Employment Law Perspectives
Oncology Care First: What You Need to Know About the Proposed Oncology Care First Model
18 November 2019
Health Care Law Today
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call